Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics.
Ghana
cluster randomized trial
typhoid conjugate vaccine
typhoid fever
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
10
02
2021
revised:
12
03
2021
accepted:
15
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Typhoid fever remains a significant health problem in sub-Saharan Africa, with incidence rates of >100 cases per 100,000 person-years of observation. Despite the prequalification of safe and effective typhoid conjugate vaccines (TCV), some uncertainties remain around future demand. Real-life effectiveness data, which inform public health programs on the impact of TCVs in reducing typhoid-related mortality and morbidity, from an African setting may help encourage the introduction of TCVs in high-burden settings. Here, we describe a cluster-randomized trial to investigate population-level protection of TYPBAR-TCV
Identifiants
pubmed: 33808924
pii: vaccines9030281
doi: 10.3390/vaccines9030281
pmc: PMC8003794
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European and Developing Countries Clinical Trials Partnership
ID : RIA2017S-2027
Organisme : Bill and Melinda Gates Foundation
ID : OPP1205877
Références
EClinicalMedicine. 2020 Sep 09;27:100540
pubmed: 33150320
BMJ. 2019 Jan 22;364:k5322
pubmed: 30670452
Clin Infect Dis. 2019 Oct 30;69(Suppl 6):S422-S434
pubmed: 31665779
Clin Infect Dis. 2018 Jun 18;67(1):18-24
pubmed: 29351594
Demography. 2005 Feb;42(1):1-22
pubmed: 15782893
Bull World Health Organ. 2004 May;82(5):346-53
pubmed: 15298225
Lancet Glob Health. 2017 Mar;5(3):e310-e323
pubmed: 28193398
PLoS Negl Trop Dis. 2016 Apr 15;10(4):e0004616
pubmed: 27082958
Vaccine. 2020 Apr 23;38(19):3518-3523
pubmed: 32201138
Clin Infect Dis. 2020 Jul 29;71(Supplement_2):S155-S159
pubmed: 32725230
BMC Infect Dis. 2016 Dec 5;16(1):732
pubmed: 27919235
Lancet Glob Health. 2014 Oct;2(10):e570-80
pubmed: 25304633
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S74-S82
pubmed: 30845333
Clin Infect Dis. 2019 Oct 30;69(Suppl 6):S417-S421
pubmed: 31665772
Clin Infect Dis. 2020 Jul 29;71(Supplement_2):S172-S178
pubmed: 32725235
N Engl J Med. 2019 Dec 5;381(23):2209-2218
pubmed: 31800986
Lancet Infect Dis. 2011 Jun;11(6):482-7
pubmed: 21616458
BMJ Open. 2018 Dec 19;8(12):e021438
pubmed: 30573477
Vaccine. 2018 Jun 18;36(26):3794-3801
pubmed: 29776750
Lancet Infect Dis. 2014 Feb;14(2):119-29
pubmed: 24290843
Infect Immun. 1999 Nov;67(11):5806-10
pubmed: 10531232
Clin Infect Dis. 2019 Oct 30;69(Suppl 6):S459-S465
pubmed: 31665774
Lancet Infect Dis. 2019 Apr;19(4):369-381
pubmed: 30792131
Vaccine. 2019 Jan 7;37(2):214-216
pubmed: 29661581
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Glob Health. 2012 Jun;2(1):010401
pubmed: 23198130
Vaccine. 2020 Jun 9;38(28):4476-4483
pubmed: 31585725
Clin Infect Dis. 2020 Sep 22;:
pubmed: 32964216
ANZ J Surg. 2009 Jul;79(7-8):565-70
pubmed: 19694672